Two Sigma Securities, LLC Neurocrine Biosciences Inc Transaction History

Two Sigma Securities, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$130.4 - $143.74 $101,320 - $111,685	777 Added 48.47%	2,380 $328,000
Q4 2023 Feb 14, 2024	BUY	$106.07 - $132.76 $170,030 - $212,814	1,603 New	1,603 $211,000
Q2 2023 Aug 14, 2023	BUY	$89.53 - $104.87 $41,004 - $48,030	458 Added 10.45%	4,839 $456,000
Q1 2023 May 15, 2023	BUY	$94.11 - $123.02 $211,182 - $276,056	2,244 Added 105.01%	4,381 $443,000
Q4 2022 Feb 14, 2023	BUY	$106.72 - $127.06 $228,060 - $271,527	2,137 New	2,137 $255,000
Q2 2022 Aug 15, 2022	BUY	$75.79 - $100.07 $210,165 - $277,494	2,773 New	2,773 $270,000
Q4 2020 Feb 16, 2021	SELL	$86.91 - $108.33 $350,768 - $437,219	-4,036 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$96.16 - $135.15 $388,101 - $545,465	4,036 New	4,036 $388,000

631

93.9M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $14B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Two Sigma Securities, LLC, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Securities, LLC with notifications on news.